CD8A and neoplasm: In the murine B16 melanoma model, VEGFC was shown to contribute to tumor immune tolerance by promoting naive T cell loss in sentinel LNs and cross-presenting tumor antigens by LECs, leading to CD8+ T cell dysfunction and apoptosis [7].